Clal Biotech 2025: MediWound Holds The Value, But Cash Holds The Risk

Getting To Know The Company

Clal Biotech is not a biotech operating company in the usual sense. It is a thin holding-company wrapper sitting above a narrower life-sciences portfolio, and almost the entire economic reading starts with one question: how much of that value is actually accessible to the public shareholders of the listed parent, and how much remains trapped inside one quoted holding plus a few private assets marked at fair value.

What is working now? The company still owns one asset that is real, public, and sellable in the market: MediWound. At the end of 2025 CBI held about 11.3% of MediWound, with a market value of about NIS 85.7 million on December 31, 2025 and about NIS 75 million near the report date. That one asset alone explains a large part of the gap between reported book value and the way the stock can be read economically. Beyond that, Biokine paid a dividend of about NIS 0.5 million, Pi-Cardia has already reached FDA clearance in the US, and MediWound itself still looks like a company with an approved product, an expanded manufacturing plant, and an active clinical program.

What is still not clean? The parent ended 2025 with only about NIS 1.7 million of cash and cash equivalents, against a controlling-shareholder loan of about NIS 16.2 million that is classified as current and due in December 2026. This is not just a gross-debt issue. The loan terms require the company to keep at least one million MediWound shares and prevent it from taking new financing or pledging assets until full repayment. So even if value exists on paper, the path from value to free cash is narrower than a superficial reading suggests.

The easiest mistake here is to spot the discount to MediWound and immediately conclude that the market is simply wrong. That is not the full story. A current market cap of about NIS 51.4 million, based on a last price of 31.9 agorot and 161.3 million shares outstanding, does look low versus the market value of the MediWound stake alone. But this is exactly the distinction between value created and value accessible. To close that gap, CBI still needs a concrete funding, monetization, or refinancing path. For now, that remains the active bottleneck.

There is also a plain actionability constraint. On the latest trading day in the local market snapshot, turnover was only about NIS 15.4 thousand. This is a very thin stock. So even if the paper thesis looks strong, the market’s ability to close pricing gaps quickly is far from guaranteed.

The Economic Map

Strengths And Risks Already Visible In The Numbers

Events And Triggers

MediWound Remains The Heart Of The Story

The first trigger: MediWound remained the only holding that truly carries the company. In September 2025 it raised about $30 million gross in an equity offering at $17.3 per share. During 2025 it also completed the expanded NexoBrid manufacturing plant, designed to increase production capacity by as much as six times, although full product availability still depends on regulatory reviews and approvals expected during 2026. In addition, the global Phase 3 VALUE trial for EscharEx was launched in February 2025, with management pointing to sample-size interim analysis and patient recruitment completion by the end of 2026.

The second trigger: MediWound is not just a commercial story. It ended 2025 with about $53.1 million of liquid assets after years of support from BARDA and the US Department of War. That matters because it means CBI’s anchor asset is not in survival mode. At the same time, it also means the market is likely to start measuring it less by basic runway and more by whether expanded manufacturing, grants, and trials can translate into a cleaner commercial profile.

The Parent Continued To Shrink Overhead And Sell Assets

The third trigger: The parent itself kept working on liquidity. During 2025 the company monetized holdings for about NIS 2.8 million, mainly through selling about NIS 1.5 million of MediWound shares and about NIS 1.3 million of Elicio shares. It also received a dividend of about NIS 0.5 million from Biokine. This is not a growth strategy. It is a liquidity-maintenance strategy.

The fourth trigger: The cost cuts are real, not just narrative. The controlling shareholder waived 25% of the monthly chairman-services fee starting in January 2024. Avi Fischer was appointed CEO in May 2024 without additional compensation beyond the chairman-services arrangement. After the balance-sheet date, in March 2026, the office sublease was amended again, reducing monthly rent and related charges to about NIS 12 thousand. This is not enough to change the cash picture by itself, but it clearly shows the company understands that the real issue sits at parent level, not only inside the portfolio.

Colospan And Pi-Cardia Sharpen What Is Left Of The Private Basket

The fifth trigger: Colospan moved in March 2026 from being a private medtech option with regulatory promise into something much closer to a damage-limitation event. The non-binding MOU speaks about $2.5 million in cash plus acquiring-company shares worth $2 million, with a 24-month lock-up and 10% of the consideration held in escrow. Based on the information available to CBI, Anatomia’s share of the total consideration is expected to amount to roughly 10% to 15%. If the deal is not completed, the company itself warns there is a material concern that Colospan may not be able to continue operating. This is not clean upside. It is mainly a mechanism to stop further deterioration.

The sixth trigger: Pi-Cardia is the clearer positive signal inside the private basket. After receiving FDA clearance in October 2024, it reported its first commercial US procedures in March 2025. It raised about $15 million in May 2025 through convertible notes, and another roughly $4 million in February 2026. But the read still has to stay sober. The fair value assigned to CBI’s and Anatomia’s holdings in Pi-Cardia was only about NIS 2.4 million at end-2025. So even with clearance and financing, the private market is still giving only cautious credit to commercialization.

That chart matters more than the headline total. The private basket is no longer broad and diversified. It is narrower, smaller, and more dependent on holdings that still have not proved full commercialization.

Efficiency, Profitability, And Competition

The wrong way to read 2025 at CBI is to ask whether gross margin improved. A holding company like this barely has an operating revenue engine at parent level. In 2025 revenue from services was zero. So the real question is not margin. It is how the loss was built, how much came from valuation, how much from the losses of associates, and how much from the parent overhead itself.

At first glance, 2025 looks like a less bad year: the annual loss fell to about NIS 20.2 million, from about NIS 75.1 million in 2024. But that improvement needs to be unpacked. On the positive side, the company booked NIS 10.7 million of gains from realization and dilution of holdings in associates, versus NIS 8.0 million in 2024. Finance expense almost disappeared, down to only NIS 0.17 million from NIS 3.9 million. G&A also fell to NIS 4.7 million.

On the other hand, the story remains negative in two heavy lines: NIS 12.3 million of losses from associates, and NIS 14.5 million of losses from the sale and fair-value remeasurement of financial assets. So this is not a clean recovery year. It is a year in which some accounting pressure eased while the portfolio still continued to lose value.

The Parent-Level Cost Cuts Are Real

The positive part of 2025 should not be dismissed. G&A fell from NIS 10.3 million in 2023 to NIS 6.6 million in 2024 and NIS 4.7 million in 2025. Salary and employee-related expense fell to NIS 1.1 million, rent and maintenance to NIS 146 thousand, and other expenses to NIS 807 thousand. Professional fees also fell to NIS 2.4 million. That means the company is doing the right thing at the parent: it is trying to extend runway without carrying unnecessary overhead.

But this also needs perspective. Cost cutting at the top does not solve the main problem because overhead is no longer the biggest issue. When debt to the controlling shareholder stands at more than nine times cash, the real question is not only what the parent costs, but in what order and on what terms a liquid asset can be turned into free cash.

The Core Metric Is MediWound, Not The Parent

If the goal is to understand CBI’s earnings quality, you have to look through to MediWound. That holding determines both the core economic value and a large part of the loss CBI books through associates.

MediWound ended 2025 with revenue of about NIS 58.5 million, down from about NIS 82.4 million in 2024. According to management, the main reason was the US government shutdown, which delayed budget approvals and additional development agreements, alongside lower NexoBrid sales by Vericel. Comprehensive loss narrowed to about NIS 82.5 million from about NIS 111.8 million in 2024, but again the reason matters: part of the improvement came from lower finance and other expenses, not from a clean commercial acceleration.

So the anchor asset is real, but it has not yet reached a point where it can be read through stable and growing profitability. It is still the story of an approved product with real commercial activity, layered with a heavy development program that consumes cash and still needs more proof.

Competition Does Not Sit At The Parent

CBI itself has no customers. It does not compete at parent level on price or volume. Competition sits inside the portfolio, and mainly inside each holding’s ability to reach a stage where the market is willing to pay up for it instead of merely continuing to finance it.

In MediWound, the competition is between clinical promise and commercial adoption. In Pi-Cardia, it is between FDA clearance and true market traction. In Colospan, the question is already less competitive and more existential. So the right reading is that CBI does not need to “win competition” at the parent level. It needs at least one holding beyond MediWound to become a credible source of value rather than just another fair-value line.

Cash Flow, Debt, And Capital Structure

Cash Flow: This Is An All-In Cash Flexibility Story

Here it is critical not to confuse recurring cash generation with all-in cash flexibility. For CBI, the right frame is all-in cash flexibility, meaning how much cash remains after the period’s actual cash uses.

In 2025 operating cash flow was negative by about NIS 4.0 million. Investing cash flow was positive by about NIS 3.3 million, mainly because of financial-asset realizations and a dividend from an associate. Financing cash flow was negative by about NIS 1.6 million, mainly because of repayment to the controlling shareholder, lease principal, and interest. The bottom line was a drop of about NIS 2.3 million in cash, from about NIS 4.0 million to about NIS 1.7 million.

That is a material point. The company does not fund itself from operations. It funds itself from realizations, dividends, and deferred debt. So the positive investing-cash-flow line here is not a sign of growth. It is a sign that the company had to harvest value in order to maintain the parent.

The Debt Is The Story, Not Just A Liability Line

The controlling-shareholder loan stood at about NIS 16.2 million on the balance sheet at end-2025, with principal plus accrued interest of about NIS 16.9 million. In August 2025 the maturity was extended to December 31, 2026, and the rate was reset to 5% from September 11, 2025. The loan is unsecured and has no financial covenants, but that is exactly why the economic restrictions around it matter: CBI committed to keep at least one million MediWound shares, avoid new financing, and avoid pledging assets until full repayment.

That changes the entire reading of the discount. If the company had NIS 15 million to NIS 20 million of cash on hand, the gap could be read mainly as a market issue. Here the debt-to-cash ratio is about 9.6 times. So even if MediWound is worth much more than its carrying value, the route to shareholder-level value still requires a concrete funding event.

Value Created In MediWound Is Large, But Not Fully Free

At the end of 2025 CBI’s equity stood at about NIS 22.9 million. If you replace only the MediWound stake from carrying value of about NIS 29.3 million to market value of about NIS 85.7 million, adjusted equity rises to about NIS 79.3 million. That is a very large gap versus a year-end market cap of about NIS 49.0 million, and versus about NIS 51.4 million in the latest local market snapshot.

But again, the easy conclusion should be resisted. Cash plus the private basket together amount to only about NIS 9.1 million. The controlling-shareholder loan alone is materially larger. So the market is not pricing only the question “what is MediWound worth?” It is also pricing “at what price, at what speed, and under what constraints can that value become accessible cash?”

That means the discount is not merely an accounting blind spot. It is also an accessibility discount. As long as the company must keep a minimum MediWound stake, cannot raise new parent-level financing, and remains dependent on orderly sales or refinancing, the gap does not have to close quickly.

The Private Basket Itself Is Less Stable Than The Headline Suggests

Fair-value financial assets fell sharply, from NIS 22.9 million to NIS 7.4 million. Colospan alone accounted for an about NIS 11.1 million write-down, and Pi-Cardia for another about NIS 2.5 million. At the same time, FDNA still represents roughly NIS 3.2 million of value, but the filing does not disclose a near-term monetization path or operating catalyst that clearly translates that mark into parent-level cash.

That is exactly why a private holding is not equivalent to a quoted screen asset. If anything, 2025 sharpened the idea that the private basket is optional upside, not the value base.

Outlook

Five findings that need to sit in the reader’s head before the detail:

1. The discount to MediWound is real, but it is not cash. As long as the parent-level debt remains unresolved, the relevant question is not only what the asset is worth, but what can actually be done with it.
2. 2025 did not prove a recovery in the private basket. It mainly showed that the parent managed to limit damage while the portfolio kept shrinking.
3. Colospan looks more like a reset in expectations than a value-creation event. The new mark is based on a non-binding MOU, a 24-month lock-up, and a material concern around continued operations if the deal fails.
4. Pi-Cardia proves the portfolio still contains some real positives, but not yet enough to change the whole thesis by itself.
5. 2026 is a bridge year trying to become a proof year. At both the parent and MediWound layers, the market will want a cleaner path from theoretical value to accessible value.

What Has To Happen At MediWound

For CBI, 2026 at MediWound is a double proof year. On one side, the expanded NexoBrid plant is already complete, but full product availability still depends on regulatory reviews and approvals. On the other side, EscharEx is already in Phase 3, with management aiming for sample-size interim analysis and recruitment completion by the end of 2026, while also planning a Phase 2 US study against SANTYL and another study in diabetic foot ulcers during 2026.

The important point is that MediWound itself expects R&D expense of about $26.2 million in 2026, versus about $14.3 million in 2025. That means the coming year is not a harvest year. It is a year in which the company is increasing clinical investment to try to convert an advanced pipeline into a wider commercial path. CBI needs that to work, but it also needs MediWound to remain liquid and strong enough to serve as the parent’s anchor asset.

What Has To Happen At The Parent

At the parent level there are four very clear checkpoints:

The key point is that the market will read every move in MediWound not only through value, but through funding. If MediWound rises, the parent’s room to maneuver looks better. If it weakens, the reading will quickly shift to repayment risk.

What Has To Happen In The Private Basket

The private part of the portfolio does not necessarily have to rescue CBI, but it does need to stop deteriorating. Colospan needs either a binding deal or an alternative financing route that takes it out of the existential zone. Pi-Cardia needs to show that early US commercialization is not just a headline but the beginning of a measurable market. FDNA at least needs to hold its current value without another negative surprise.

All of this means the coming year is not a breakout year for CBI. It is a transition year centered on one test: can the company move from a situation in which it relies on value on paper to one in which it has a cleaner cash and funding path?

Risks

The first risk is concentration. MediWound is simultaneously the main source of value, the main source of possible liquidity, and a major driver of the stock’s sensitivity. If MediWound weakens materially, adjusted equity, repayment flexibility, and market confidence in the discount can all deteriorate together.

The second risk is parent-level funding. Management states that its liquid resources, cash plus quoted portfolio holdings, should allow repayment of the loan and continuation of operations for the next 12 months. That matters, but it does not remove the event. Anyone reading 2026 has to understand that the year will still be judged through a concrete funding test.

The third risk is the quality of the private marks. Pi-Cardia was valued using a VC framework with a 4.4 sales multiple, a 42.5% discount rate, and 56% volatility. Colospan now rests on a non-binding MOU and a 27.5% lock-up discount. These are not good or bad numbers in themselves. They are simply more fragile than a quoted public holding.

The fourth risk is capital-markets and external backdrop. The company itself says that war, higher rates, and FX volatility have hurt the fundraising ability of Israeli companies and the valuation of portfolio holdings. On top of that, during 2025 US tariff policy tightened on imports of medical equipment, components, and modules. This does not break CBI tomorrow morning, but it does sharpen the point that the portfolio sits in an industry that depends on both capital access and market-entry conditions.

The fifth risk is the stock’s own liquidity. The latest local short-interest snapshot points to a negligible short position, with short float at 0% and SIR at 0 in the latest observation, after only a temporary peak of about 0.17% in April 2025. So the issue is not an aggressive short book. The issue is that the stock is extremely thin, which means price reactions can still be sharp even without meaningful bearish positioning.

Conclusions

Clal Biotech exits 2025 as a holding company that is both narrower and clearer than it used to be. This is no longer a broad life-sciences basket that might one day re-rate as a whole. It is mainly one anchor asset in MediWound, a thin parent layer, a private basket that has been cut down, and a controlling-shareholder loan that forces the company to prove a liquidity path into the end of 2026.

What supports the thesis today is that MediWound still carries far more market value than the book value CBI recognizes, and that the quoted value of that one stake still exceeds CBI’s own market cap. The main blocker is that the value is not free: there is debt, there are capital-structure restrictions, and the cash cushion is thin. What will shape market reaction in the short to medium term is not another abstract discussion of discount, but any real sign of repayment, refinancing, or orderly monetization.

Current thesis: CBI trades at a real discount to the economic value of MediWound, but that discount will persist as long as the company does not turn that value into a cleaner cash and funding path.

What changed versus the old understanding of the company? 2025 made it clear that this is no longer a “life-sciences portfolio” story. It is a MediWound story, plus a few private options that are no longer strong enough to carry the thesis on their own. At the same time, the controlling-shareholder loan moved from a background capital-structure issue to the core lens for 2026.

The strongest counter-thesis is that the market may simply be too conservative. If the MediWound stake alone was worth about NIS 85.7 million at the end of 2025, and if CBI only needs to retain at least one million shares rather than the entire position, the pricing gap may be too large relative to the real funding risk. On top of that, if Pi-Cardia starts to convert regulatory progress into visible commercialization, or if Colospan closes a binding transaction, there may be more upside inside the private basket than the market currently gives credit for.

What could change the market’s interpretation in the short to medium term? Any concrete sign of loan repayment or refinancing, a sharp move in MediWound shares, regulatory progress around MediWound’s expanded manufacturing plant, or a material update from Colospan and Pi-Cardia.

Why does this matter? Because in CBI the value is mostly created outside the listed company, while the risk sits inside the parent. If you do not separate economic value from accessible value, you miss the core of the story.

Over the next 2 to 4 quarters, the thesis strengthens if the company shows an orderly repayment or refinancing path, preserves value and liquidity through MediWound, and stops the private basket from deteriorating further. It weakens if MediWound’s value falls materially, if management cannot present a clean funding route into December 2026, or if the private portfolio takes another round of write-downs.